Selective modulation of the cannabinoid type 1 (CB1) receptor as an emerging platform for the treatment of neuropathic pain

Samuel D. Banister, Kaavya Krishna Kumar, Vineet Kumar, Brian K. Kobilka, Sanjay V. Malhotra

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Neuropathic pain is caused by a lesion or dysfunction in the nervous system, and it may arise from illness, be drug-induced or caused by toxin exposure. Since the discovery of two G-protein-coupled cannabinoid receptors (CB1 and CB2) nearly three decades ago, there has been a rapid expansion in our understanding of cannabinoid pharmacology. This is currently one of the most active fields of neuropharmacology, and interest has emerged in developing cannabinoids and other small molecule modulators of CB1 and CB2 as therapeutics for neuropathic pain. This short review article provides an overview of the chemotypes currently under investigation for the development of novel neuropathic pain treatments targeting CB1 receptors.

Original languageEnglish (US)
Pages (from-to)647-659
Number of pages13
JournalMedChemComm
Volume10
Issue number5
DOIs
StatePublished - 2019
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Selective modulation of the cannabinoid type 1 (CB<sub>1</sub>) receptor as an emerging platform for the treatment of neuropathic pain'. Together they form a unique fingerprint.

Cite this